Live feed07:00:30·2015dANALYSTRatingvia QuantisnowRaymond James initiated coverage on Neurocrine Biosciences with a new price targetByQuantisnow·Wall Street's wire, on your screen.NBIX· Neurocrine Biosciences Inc.Health CareOriginal source